OX40配体/OX40轴信号在特应性皮炎中的作用
本文综述OX40L/OX40共刺激信号在特应性皮炎(AD)发病中的作用。AD影响全球每10人中的2–3人,OX40L/OX40可促进Th2、Th1、Th17和Th22等多条通路中致病T细胞的增殖与存活,放大并维持慢性炎症。近期临床试验的治疗成功提示该轴是AD有前景的靶点,阻断OX40L与OX40的相互作用可能缓解或阻止AD症状。
要点
- OX40L/OX40是共刺激免疫检查点分子,调控效应与记忆T细胞活性。
- AD中OX40L/OX40信号促进T细胞介导炎症的放大和慢性持续。
- 阻断OX40L与OX40相互作用是中度至重度AD的潜在治疗方向。
核心结论
- OX40L/OX40轴在AD的T细胞炎症放大与慢性持续中起重要作用,是AD治疗的有前景靶点。
- 阻断OX40L与OX40的相互作用可能缓解或阻止AD症状。
研究设计与样本
- 综述:讨论OX40L和OX40表达的相关因素,包括细胞因子环境、抗原呈递、AD炎症环境及该共刺激通路的治疗方向。
主要发现
- OX40L/OX40信号调控效应与记忆T细胞活性,并促进包括Th2、Th1、Th17和Th22在内的多条免疫通路中的持续免疫反应。
- 抗原呈递细胞与识别抗原后活化T细胞之间的OX40L/OX40信号促进致病T细胞增殖与存活。
- 炎症条件下抗原呈递细胞上OX40L上调,增强抗原特异性T细胞反应强度和促炎细胞因子分泌。
- AD中OX40L/OX40信号参与T细胞介导炎症的放大和慢性持续。
- 近期临床试验的治疗成功凸显OX40L/OX40轴作为AD有前景治疗靶点的重要性。
关键数值与推荐
- AD影响全球每10人中的2–3人,累及所有年龄段,可致皮肤干燥增厚、瘙痒、皮疹和疼痛。
- 尽管已有新的靶向治疗选择,中度至重度AD患者仍需新疗法。
临床怎么用
- 综述提示可关注靶向OX40L/OX40相互作用的在研药物,作为中度至重度AD的潜在治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atopic dermatitis (AD) is a heterogeneous inflammatory condition involving multiple immune pathways mediated by pathogenic T cells. OX40 ligand (OX40L) and OX40 are costimulatory immune checkpoint molecules that regulate effector and memory T-cell activity and promote sustained immune responses in multiple immunological pathways, including T helper (Th)2, Th1, Th17 and Th22. As such, OX40L/OX40 signalling between antigen-presenting cells (APCs) and activated T cells postantigen recognition promotes pathogenic T-cell proliferation and survival. Under inflammatory conditions, OX40L is upregulated on APCs, enhancing the magnitude of antigen-specific T-cell responses and secretion of proinflammatory cytokines. In AD, OX40L/OX40 signalling contributes to the amplification and chronic persistence of T-cell-mediated inflammation. Recent therapeutic success in clinical trials has highlighted the importance of the OX40L/OX40 axis as a promising target for the treatment of AD. Here, we discuss the many factors that are involved in the expression of OX40L and OX40, including the cytokine milieu, antigen presentation, the inflammatory environment in AD, and the therapeutic direction influenced by this costimulatory pathway. Atopic dermatitis (AD) (also known as atopic eczema) is a common skin disease caused by inflammation, and affects 2–3 of every 10 people worldwide. AD affects people of all ages and can cause a range of symptoms, including dry thickened skin, itchiness, rashes and pain. Despite the recent addition of new targeted treatment options, there is still a need for new treatments for people with moderate-to-severe AD. New drugs are being studied that target two important signalling molecules in the immune system, called OX40 ligand (OX40L) and OX40. OX40L and OX40 bind together to continue the cycle of immune system activation, leading to increasing symptoms of AD. Blocking the OX40L and OX40 interaction may ease or stop symptoms of AD. This review outlines what is currently known about the causes of AD, including the role played by the immune system and specifically the role of OX40L and OX40. We also highlight the development of new treatments that target the OX40L and OX40 interaction to treat AD, and suggest what the future may hold for managing AD.
引用
- Guttman-Yassky E, Croft M, Geng B, et al. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. Br J Dermatol. 2024. PMID: 38836560. doi:10.1093/bjd/ljae230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。